Selecta Biosciences, Inc. (NASDAQ:SELB) insider Earl Sands bought 7,500 shares of the stock in a transaction on Friday, November 17th. The stock was purchased at an average cost of $10.26 per share, for a total transaction of $76,950.00. Following the acquisition, the insider now directly owns 7,500 shares of the company’s stock, valued at approximately $76,950. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Selecta Biosciences, Inc. (SELB) traded up $0.38 on Friday, hitting $10.18. The company had a trading volume of 202,800 shares, compared to its average volume of 112,689. The company has a current ratio of 9.48, a quick ratio of 9.48 and a debt-to-equity ratio of 0.32. Selecta Biosciences, Inc. has a fifty-two week low of $8.70 and a fifty-two week high of $28.00.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Selecta Biosciences, Inc. (SELB) Insider Acquires $76,950.00 in Stock” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/24/insider-buying-selecta-biosciences-inc-selb-insider-acquires-76950-00-in-stock.html.

Several research firms have weighed in on SELB. Zacks Investment Research raised Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Saturday, November 11th. UBS AG lowered Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Canaccord Genuity reissued a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a report on Tuesday, November 7th. Finally, ValuEngine lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Selecta Biosciences presently has an average rating of “Buy” and an average target price of $25.20.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors boosted its stake in shares of Selecta Biosciences by 224.5% during the second quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after acquiring an additional 4,561 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Selecta Biosciences by 827.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock valued at $224,000 after acquiring an additional 10,040 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Selecta Biosciences during the second quarter valued at $239,000. New York State Common Retirement Fund boosted its stake in shares of Selecta Biosciences by 184.0% during the second quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock valued at $248,000 after acquiring an additional 8,099 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Selecta Biosciences during the first quarter valued at $211,000. 53.13% of the stock is currently owned by institutional investors and hedge funds.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.